SNPX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
SNPX 近期報酬表現
-1.05%
Synaptogenix inc
1.56%
同產業平均
1.17%
S&P500
與 SNPX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
THRD | Third harmonic bio inc | - | 5 分 | 3 分 | 2 分 | 1 分 | |
TSBX | Turnstone biologics corp | - | 2 分 | 2 分 | 1 分 | 1 分 | |
AFMD | Affimed nv | 3 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
PCRX | Pacira biosciences inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
CYBN | Cybin inc | 1 分 | 2 分 | 2 分 | - | 1 分 |
- THRD Third harmonic bio inc價值 -趨勢 5 分波段 3 分籌碼 2 分股利 1 分查看更多
SNPX 公司資訊
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.